Education Sessions

Cancer Fatigue and Contributing Factors: Recognition and Treatment
  Ann Malone Berger, RN, PhD, AOCN, FAAN – Chair
  Eduardo Bruera, MD
  Bernadine Cimprich, RN, PhD, CS, FAAN

Standards of Care in Advanced Renal Cell Carcinoma
  Primo Lara Jr., MD – Chair
  Christopher W. Ryan, MD
  Eric Jonasch, MD

Management of Side Effects of the Treatment of Colorectal Cancer
  Howard S. Hochster, MD—Chair
  Bruce D. Minsky, MD
  Mario E. Lacouture, MD

Updates in Hormone Receptor-positive, HER2-positive, and Triple-negative Breast Cancer
  Lisa A. Carey, MD—Chair
  Mitchell Dowsett, PhD
  Olufunmilayo I. Olopade, MBBS, FACP

Adjuvant Treatment in Patients over Age 75: When to Treat and When Not to Treat
  Peter Ravdin, MD—Chair
  Supriya Gupta Mohile, MD, MS
  Arash Naeim, MD

Evolving Standards of Care in Metastatic Castration resistant Prostate Cancer
  Michael J. Morris, MD—Chair
  Kim N. Chi, MD
  Evan Y. Yu, MD

Maintenance Chemotherapy for Non-small Cell Lung Cancer: Effectiveness and Cost-effectiveness
  Tom Stinchcombe, MD—Chair
  Tracey L. Evans, MD
  Scott Ramsey, MD, PhD
Early-stage Non-small Cell Lung Cancer: Staging and Primary Treatment
Harvey I. Pass, MD—Chair
Scott Shofer, MD, PhD
Andrea Bejzak, MD

Supportive Care for Patients with Non-small Cell Lung Cancer
Minesh P. Mehta, MD—Chair
David J. Feller-Kopman, MD
Vera Hirsh, MD

Management of the Elderly Patient with Cancer
Elizabeth B. Lamont, MD, MS—Chair
Cary P. Gross, MD
Arti Hurria, MD

Science Sessions

Plenary Session
Including Science of Oncology Award and Lecture
Douglas W. Blayney, MD; Co-Chair
Daniel F. Hayes, MD; Co-Chair

Abstract 1
Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): A Gynecologic Oncology Group study
Presenter – R.A. Burger, MD
Discussant – Elisabeth A. Eisenhauer, MD

Abstract 2
Weekly paclitaxel combined with monthly carboplatin versus single-agent therapy in patients age 70 to 89: IFCT-0501 randomized phase III study in advanced non-small cell lung cancer (NSCLC)
Presenter – E.A. Quiox, MD
Discussant – Martin J. Edelman, MD

Abstract 3
Clinical activity of the oral ALK inhibitor, PF-02341066, in ALK-positive patients with non-small cell lung cancer (NSCLC)
Presenter – Y. Bang, MD
Discussant – Martin J. Edelman, MD

Abstract 4
A phase III, randomized, double-blind, multicenter study comparing the monotherapy with ipilimumab or gp100 peptide vaccine and the combination in patients with previously treated, unresectable stage III or IV melanoma
Presenter – S. O’Day, MD
Discussant – Vernon K. Sondak, MD
Highlights of the Day I
Everett E. Vokes, MD; Co-Chair
Douglas W. Blayney, MD; Co-Chair
Bruce D. Cheson, MD – Lymphoma and Plasma Cell Disorders
Alan B. Sandler, MD – Lung Cancer – Local-Regional and Adjuvant Therapy
Gretchen Genevieve Kimmick, MD – Patient and Survivor Care
F. Stephen Hodi, MD – Melanoma/Skin Cancers

Highlights of the Day II
Kim Allyson Margolin, MD; Co-Chair
Douglas W. Blayney, MD; Co-Chair
Nicholas J. Vogelzang, MD – Genitourinary (Prostate) Cancer
Howard S Hochster, MD – Gastrointestinal (Colorectal) Cancer
Claire F. Verschraegen, MD – Gynecologic Cancer
Jean-Luc Harousseau, MD – Myeloma
Scott Michael Lippman, MD – Cancer Prevention/Epidemiology

Highlights of the Day III
Kathy Miller, MD; Chair
Charles M. Rudin, MD,PhD – Lung Cancer – Metastatic
Gary K Schwartz, MD – Sarcoma
Charles K. Blanke, MD – Gastrointestinal (Noncolorectal) Cancer
Everett E. Vokes, MD – Head and Neck Cancer
Richard M. Stone, MD – Leukemia, Myelodysplasia, and Transplantation